PR
PROT.US Proteonomix Inc
- Market cap
- USD 791.00
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2012.
Is PROT.US undervalued?
Graham numberThe Graham number of Proteonomix Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Proteonomix Inc fundamental analysis
No fundamental analysis for Proteonomix Inc yet.
Proteonomix Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Proteonomix Inc
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two we…
Full company profileProteonomix Inc financial statements
2012 annualized: Fiscal year 2012 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2012, the balance sheet is the latest quarter. Figures change when the annual report is published.
Proteonomix Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2008 | 2009 | 2010 | 2011 | 2012 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 132K | 142K | 83.3K | 26.0K | 4.58K |
| Gross Profit | 115K | 118K | 67.5K | 26.5K | 3.41K |
| Operating Income | -4.86M | -3.82M | -3.45M | -1.31M | -5.95M |
| Net Income | -4.97M | -3.86M | -3.47M | -1.38M | -1.50M |
| Balance Sheet | |||||
| Total Assets | 420K | 411K | 3.65M | 3.34M | 5.75M |
| Total Liabilities | 7.84M | 4.90M | 7.10M | 7.04M | 5.76M |
| Shareholders' Equity | -7.42M | -4.49M | -3.44M | -3.70M | -1.69K |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow | |||||
| Operating Cash Flow | -111K | -206K | -565K | -277K | -1.02M |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 694.40 |
| Ratios | |||||
| ROA | -1,182.8% | -938.6% | -95.0% | -41.4% | -26.0% |
| Net Profit Margin | -3,763.6% | -2,723.7% | -4,164.7% | -5,321.7% | -32,691.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Proteonomix Inc dividends
Proteonomix Inc has not paid dividends in the last 4 fiscal years.
Last stock split: 1:10 on Aug 21, 2008.
Who owns Proteonomix Inc
Ownership data of Proteonomix Inc is not available yet.
Proteonomix Inc company profile
- Company name
- Proteonomix Inc
- Ticker
- PROT.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- 145 Highview Terrace, Hawthorne, NJ, United States, 07506
- Phone
- 973-949-4193
- Website
- proteonomix.com
About Proteonomix Inc
Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.
Proteonomix Inc management
2- Mr. Michael CohenFounder, Chairman, CEO, President & COO · born 1967
- Mr. Steven Byle J.D.CTO & Director · born 1968